Net Deals Web Search

Search results

  1. Results From The WOW.Com Content Network
  2. Oxford–AstraZeneca COVID-19 vaccine - Wikipedia

    en.wikipedia.org/wiki/Oxford–AstraZeneca_COVID...

    The Oxford–AstraZeneca COVID‑19 vaccine is used to provide protection against infection by the SARS-CoV-2 virus in order to prevent COVID-19 in adults aged 18 years and older. [ 1 ] The medicine is administered by two 0.5 ml (0.017 US fl oz) doses given by intramuscular injection into the deltoid muscle (upper arm).

  3. AstraZeneca raises profit outlook on strong medicines demand

    www.aol.com/news/astrazeneca-raises-full-outlook...

    Sales in AstraZeneca's top business, oncology, grew 19% at constant currency rates to $5.33 billion and accounted for 41% of the total, while its rare disease and heart and kidney disease ...

  4. AstraZeneca - Wikipedia

    en.wikipedia.org/wiki/AstraZeneca

    AstraZeneca plc ( / ˌæstrəˈzɛnəkə /) ( AZ) is a British-Swedish multinational pharmaceutical and biotechnology company [ 2 ][ 3 ][ 4 ] with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. [ 5 ] It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal ...

  5. Big Pharma: The government revealed its list of negotiated ...

    www.aol.com/finance/big-pharma-government...

    The Centers for Medicare and Medicaid Services (CMS) released its first-ever negotiated drug price list Thursday morning to a muted response on Wall Street. But industry and government officials ...

  6. AstraZeneca aims for $80 billion in total revenue by 2030 - AOL

    www.aol.com/news/astrazeneca-aims-80-billion...

    Show comments. AstraZeneca aims to grow revenue by about 75% to $80 billion by 2030, it said on Tuesday, boosted by the expected launch of 20 new medicines and through growth in its cancer ...

  7. Durvalumab - Wikipedia

    en.wikipedia.org/wiki/Durvalumab

    Durvalumab, [8] sold under the brand name Imfinzi, is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. [9] It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 with the PD-1 (CD279).

  8. AstraZeneca CFO: 'We've come a long way in our oncology ...

    www.aol.com/finance/astrazeneca-cfo-weve-come...

    AstraZeneca has set a target to become an $80 billion company, in sales, by 2030. ... Click here for in-depth analysis of the latest health industry news and events impacting stock prices.

  9. Vandetanib - Wikipedia

    en.wikipedia.org/wiki/Vandetanib

    Vandetanib, sold under the brand name Caprelsa, is an anti-cancer medication that is used for the treatment of certain tumours of the thyroid gland. It acts as a kinase inhibitor of a number of cell receptors, mainly the vascular endothelial growth factor receptor (VEGFR), the epidermal growth factor receptor (EGFR), and the RET -tyrosine ...